Skip to content
lifestyle.brightsfuture.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Celcuity Inc.
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
March 14, 2026
Celcuity To Participate in Upcoming Investor Conferences
March 12, 2026
Celcuity Appoints Charles Romp to its Board of Directors
March 10, 2026
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
March 8, 2026
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
January 20, 2026
←
Previous Page
1
2